ストックスクリーナーアプリを入手
72.76
6.49%
-5.05
前日終値:
$77.81
開ける：
$77.35
24時間の取引高:
853.77K
Relative Volume:
0.92
時価総額：
$5.82B
収益：
$58.89M
当期純損益:
$-240.88M
株価収益率:
-23.47
EPS:
-3.1
ネットキャッシュフロー:
$-239.96M
1週間 パフォーマンス:
-10.53%
1か月 パフォーマンス:
+13.21%
6か月 パフォーマンス:
+63.40%
1年 パフォーマンス:
+77.94%
1日の値動き範囲:
$72.16
$77.83
1週間の範囲:
$72.16
$81.94
52週間の値動き範囲:
$19.45
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
名前
Kymera Therapeutics Inc
セクター
電話
857-285-5314
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
KYMR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
72.76 | 6.22B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | 再開されました | Guggenheim | Buy |
| 2025-10-24 | 繰り返されました | B. Riley Securities | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-16 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-05-20 | 再開されました | Stifel | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-12-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-26 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 開始されました | Oppenheimer | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 開始されました | Truist | Buy |
| 2023-05-05 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 開始されました | Raymond James | Mkt Perform |
| 2022-08-15 | 開始されました | Jefferies | Buy |
| 2022-08-03 | 開始されました | Goldman | Buy |
| 2022-07-20 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | JP Morgan | Neutral |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2021-09-30 | 開始されました | B. Riley Securities | Neutral |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-09-15 | 開始されました | BofA Securities | Neutral |
| 2020-09-15 | 開始されました | Cowen | Outperform |
| 2020-09-15 | 開始されました | Guggenheim | Buy |
| 2020-09-15 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Kymera Therapeutics Inc (KYMR) 最新ニュース
Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next - ts2.tech
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3%What's Next? - MarketBeat
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - Investing.com
Kymera Therapeutics (KYMR) Sees 4% Drop in Stock Price - GuruFocus
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - MarketBeat
The Technical Signals Behind (KYMR) That Institutions Follow - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares - MarketBeat
Kymera Therapeutics Insider Sold Shares Worth $2,341,939, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching - ts2.tech
B. Riley Securities Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq
Why Kymera Therapeutics Stock Is Sliding Despite Hype - TipRanks
KYMR: B. Riley Securities Raises Price Target for Kymera Therape - GuruFocus
B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating - marketscreener.com
Can Kymera Therapeutics Inc. stock hit analyst price targets2025 Valuation Update & Daily Growth Stock Tips - Улправда
Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
What momentum indicators show for Kymera Therapeutics Inc. stockDividend Hike & Low Risk Entry Point Guides - ulpravda.ru
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 3.4%Here's What Happened - MarketBeat
Can Kymera Therapeutics Inc. stock deliver consistent earnings growth - Улправда
Kymera Therapeutics Insider Sold Shares Worth $2,264,480, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics (KYMR) Gets a Buy from Wells Fargo - The Globe and Mail
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - 24/7 Wall St.
Why Analysts See Kymera Therapeutics Differently After KT 621 Momentum And Rising Fair Value - Yahoo Finance
RBC Capital Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says - marketscreener.com
RBC Capital Raises Price Target for Kymera Therapeutics (KYMR) | - GuruFocus
RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk - marketscreener.com
Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital - Investing.com Canada
Kymera's eczema drug gets fast track designation in the United States - MSN
Obesity data, Kymera and FDA sentiment survey results — a BioCentury podcast - BioCentury
Kymera gains fast track status for oral candidate KT-621 for eczema - MSN
Kymera Therapeutics Insider Sold Shares Worth $21,699,044, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. - Barron's
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 678 Shares - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 229,809 Shares - MarketBeat
Eventide Asset Management LLC Increases Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
BVF Inc. IL Boosts Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics director Booth sells $21.7 million in stock By Investing.com - Investing.com Canada
Kymera Therapeutics director Booth sells $21.7 million in stock - Investing.com
Kymera Therapeutics Inc. (KYMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kymera Therapeutics (NASDAQ:KYMR) Director Buys $172,499,918.00 in Stock - MarketBeat
Owner Atlas Venture Fund X LP Files To Sell 570 Of Kymera Therapeutics Inc [KYMR] - TradingView — Track All Markets
Kymera Therapeutics Soars on Robust KT-621 Trial Results - timothysykes.com
Kymera jumps on early-stage data for eczema candidate KT-621 - MSN
Kymera's Eczema Drug Gets Fast Track Designation in the United States - Yahoo Finance
Kymera Therapeutics announces $500M proposed public offering - MSN
Redmile Group LLC Trims Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Frontier Capital Management Co. LLC Grows Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Mizuho Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise ... - Enidnews.com
Kymera Therapeutics Inc (KYMR) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):